IP Library Granted Patent US 9,629,881
Granted Patent B2
US 9,629,881 · App. 13/576,573 · Granted Apr 25, 2017

Bacteriotherapy for clostridium difficile colitis

Inventor: Edwin J. Hlavka (Minneapolis, MN)
Assignee: REBIOTIX, INC.
A61K35/74C12N1/04C12N1/20G01N33/56911G01N2333/33G01N2800/52
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,629,881
App. No.
13/576,573
Granted
Apr 25, 2017
Kind
B2
Abstract

This document discusses, among other things, receiving a plurality of donor fecal samples from a plurality of donors and storing and indexing each respective donor fecal samples using at least one characteristic of the respective donor fecal sample. In an example, the donor fecal sample can be screened and processed for subsequent use in fecal bacteriotherapy to displace pathogenic or undesired organisms in the digestive track of a patient with healthy or desirable gut micriobiota.

Claims (16)

1. A bacteriotherapy bank, comprising:

a temperature specific storage device;

a plurality of human fecal samples disposed in the temperature specific storage device;

the plurality of human fecal samples including a first sample from a first donor and a second sample from a second donor different from the first donor;

wherein preparing the first sample and the second sample both include:

obtaining a donor fecal sample, and

homogenizing a donor fecal sample with the at least one cryoprotectant and then filtering the homogenized composition;

wherein the first sample includes a first dietary characteristic of the first donor;

wherein the second sample includes a second dietary characteristic of the second donor different from the first dietary characteristic of the first donor;

wherein the first dietary characteristic and the second dietary characteristic are a human donor geographic consumption region, a human donor diet, a human donor religion, or combinations thereof and are configured to be matched to a human patient based on the dietary characteristic of the human donor such that a gut microbiota of the human donor and a gut microbiota of the human patient are similar following administration of the first bacteriotherapy composition to the human patient.

2. The bacteriotherapy bank of claim 1 , wherein the fecal samples are stored under temperature conditions for maintaining viability of the biota of the fecal samples.

3. The bacteriotherapy bank of claim 1 , wherein the fecal samples are contained in a plurality of storage containers configured to store each of a plurality of fecal samples.

4. The bacteriotherapy bank of claim 1 , wherein the first sample, the second sample, or both include a physical characteristic of the donor.

5. The bacteriotherapy bank of claim 4 , wherein the physical characteristic of the donor is a donor body mass index (BMI), a donor weight, a combination of a donor height and the donor weight, or a donor body fat percentage.

6. The bacteriotherapy bank of claim 4 , wherein the physical characteristic of the donor is a medical condition of the donor, or the presence or absence of a medical condition of the donor.

7. The bacteriotherapy bank of claim 1 , wherein the first sample, the second sample, or both include the geographic location of the donor, the diet source of the donor, the diet type of the donor, the ethnicity of the donor, the body type of the donor, the age of the donor, the sex of the donor, the health status of the donor, the medical history of the donor, or combinations thereof.

Assignments (3)
CHANGE OF NAME Recorded Jan 27, 2025
From: REBIOTIX INC.
To: FERRING MICROBIOME INC.
Reel/Frame 070022/0505 →
CHANGE OF NAME Recorded Dec 27, 2013
From: MIKROBEX INC.
To: REBIOTIX INC.
Reel/Frame 031871/0958 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 20, 2013
From: HLAVKA, EDWIN J.
To: MIKROBEX INC.
Reel/Frame 030052/0255 →
Continuity (3)
Provisional Application 61337283 · Feb 1, 2010
Provisional Application 61351184 · Jun 3, 2010
Related Publication 20130045274A1 · Feb 21, 2013